Recent analyses showed that the risk of relapse and death persists despite the completion of 5 years of adjuvant ET in ER+/HER2 negative BC patients (14–16), suggesting that additional parameters, beyond ER status, should be considered to identify patients who may obtain additional benefit from CT and/or extended ET. This evidence concerns the gene ESR1 and breast cancer.